Valuation: Telix Pharmaceuticals Limited

Market Cap 4.55B 3.07B 2.79B 2.58B 2.33B 4.4B 288B 31.01B 12.29B 155B 11.53B 11.28B 490B P/E 2026 *
200x
P/E 2027 * 2,313x
Enterprise Value 5.06B 3.42B 3.1B 2.87B 2.59B 4.89B 321B 34.48B 13.66B 172B 12.82B 12.55B 545B EV / Sales 2026 *
3.62x
EV / Sales 2027 * 3.12x
Free-Float
84.31%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Telix Pharmaceuticals Limited

1 day-0.45%
1 week-3.41%
Current month+1.52%
1 month-13.44%
3 months-18.97%
6 months-6.52%
Current year+19.02%
1 week 13.04
Extreme 13.04
14.35
1 month 12.61
Extreme 12.61
16.25
Current year 8.26
Extreme 8.26
18.22
1 year 8.26
Extreme 8.26
18.22
3 years 8.26
Extreme 8.26
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 03/01/2017
Director of Finance/CFO 61 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 03/01/2017
Chairman 66 03/02/2026
Director/Board Member 68 19/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
30/10/26 Buy

Director

9,000 0.0026%
29/10/26 Free

Director

1,095 0.0003%
27/10/26 Buy

Director

7,812 0.0023%
Change 5-day change 1-year change 3-year change Capi.($)
-0.45%-3.41%-6.13%+41.96% 3.07B
-1.29%-3.91%+51.98%+69.06% 65.56B
-2.28%-0.76%+8.23%+89.61% 60.41B
-0.51%+0.91%+23.66%+87.89% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
-3.15%-16.63%+146.30%+685.27% 36.09B
+0.23%+2.14%+14.85%+46.22% 36.7B
-1.03%-2.18%+77.32%+58.01% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -0.86%-1.86%+31.22%+162.75% 41B
Weighted average by Cap. -1.04%-1.60%+34.43%+149.39%

Financials

2026 *2027 *
Net sales 1.4B 945M 858M 793M 716M 1.35B 88.7B 9.54B 3.78B 47.6B 3.54B 3.47B 151B 1.59B 1.08B 977M 902M 815M 1.54B 101B 10.85B 4.3B 54.17B 4.03B 3.95B 172B
Net income 27.07M 18.28M 16.61M 15.34M 13.86M 26.15M 1.72B 185M 73.11M 921M 68.59M 67.13M 2.92B 2.65M 1.79M 1.62M 1.5M 1.36M 2.56M 168M 18.04M 7.15M 90.05M 6.71M 6.56M 285M
Net Debt 510M 345M 313M 289M 261M 493M 32.35B 3.48B 1.38B 17.36B 1.29B 1.27B 54.99B 426M 288M 261M 242M 218M 412M 27.02B 2.91B 1.15B 14.5B 1.08B 1.06B 45.93B
Projected Income Statement - Annual - Telix Pharmaceuticals Limited
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
17/11/26 $13.33 -0.45% 1,428,926
16/11/26 $13.39 -1.40% 1,105,902
13/11/26 $13.58 -0.88% 877,947
12/11/26 $13.70 -2.28% 2,345,160
11/11/26 $14.02 +1.59% 1,993,317
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Telix Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.39AUD
Average target price
24.17AUD
Spread / Average Target
+80.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Telix Pharmaceuticals Limited